Sort by
Refine Your Search
-
Program
-
Employer
-
Field
-
in digital twin modelling and general knowledge on agriculture. Eligibility: Applicants must be acceptable as candidates for a PhD degree at the University of Adelaide. Stipend: The scholarship will be
-
in immunology, cell biology, developmental biology, genetics or a related discipline (detailed admission requirements are here ) Experience in cell biology or tissue culture. Experience with
-
Experience of molecular biology laboratory protocols including tissue culture, western blots, QRT-PCR is a prerequisite. A general understanding of the pathways involved in cancer progression is suggested
-
as a world leader in the discovery and development of next-generation drugs, vaccines, and diagnostics for diseases with a global impact. Established in 2000, it is one of Australia's premier
-
groundwater (space) over time (seasonality), the baseline information generated will provide guidelines on how to maintain and rehabilitate healthy groundwater habitats. Investigations of the microbial and
-
: Candidates will need to fulfil the Monash University minimum requirements for admission to a PhD detailed here: www.monash.edu/admissions/entry-requirements/minimum How to apply For general instructions on how
-
(iPhD) is a four-year research training program, focusing on applied research that benefits industry by solving real-world challenges. It aims to produce the next generation of innovation leaders with
-
generation of innovation leaders with the skills to work at the interface of research and industry in Australia. Apply today to undertake this exciting project at the University of Adelaide. Project overview
-
), Bachelor of Commerce (Finance) Bachelor of Science (Applied Geology), Bachelor of Environmental Biology Eligibility criteria Applicants must meet all of the following criteria to be considered eligible
-
breast cancer. We believe that the generation of drugs targeting USP10 will change the current therapeutic protocols for patients with advanced breast cancer. Using new mRNA therapies, we will design ways